Jin F. Zhang

No. 225, Changhai Road
Shanghai, 200438, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: March 16, 2025

Characteristics and patient-reported outcomes of long-term cancer survivors after apatinib-based therapy: an online survey.

Characteristics and patient-reported outcomes of long-term cancer survivors after apatinib-based therapy: an online survey.

Journal: BMC cancer

Published: May 24, 2024

Discontinuation of immune checkpoint inhibitors in hepatocellular carcinoma: a retrospective cohort study.

Discontinuation of immune checkpoint inhibitors in hepatocellular carcinoma: a retrospective cohort study.

Journal: Journal of gastrointestinal oncology

Published: March 25, 2024

microRNA-2117 Negatively Regulates Liver Cancer Stem Cells Expansion and Chemoresistance Via Targeting SOX2.

microRNA-2117 Negatively Regulates Liver Cancer Stem Cells Expansion and Chemoresistance Via Targeting SOX2.

Journal: Molecular carcinogenesis

Published: March 18, 2024

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma.

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma.

Journal: Frontiers in oncology

Published: March 13, 2024

Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study.

Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study.

Journal: Frontiers in oncology

Published: February 12, 2022

Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis.

Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis.

Journal: Cell death & disease

Published: October 22, 2021

miR-96 regulates liver tumor-initiating cells expansion by targeting TP53INP1 and predicts Sorafenib resistance.

miR-96 regulates liver tumor-initiating cells expansion by targeting TP53INP1 and predicts Sorafenib resistance.

Journal: Journal of Cancer

Published: May 18, 2020

NQO1 promotes an aggressive phenotype in hepatocellular carcinoma via amplifying ERK-NRF2 signaling.

NQO1 promotes an aggressive phenotype in hepatocellular carcinoma via amplifying ERK-NRF2 signaling.

Journal: Cancer science

Published: May 16, 2020

Mean Platelet Volume/Platelet Count Ratio as a Predictor of 3-Month Mortality in HBV-Related Decompensated Cirrhosis Patients.

Mean Platelet Volume/Platelet Count Ratio as a Predictor of 3-Month Mortality in HBV-Related Decompensated Cirrhosis Patients.

Journal: Clinical laboratory

Published: March 13, 2020

Three-dimensional computed tomography mapping of posterior malleolar fractures.

Three-dimensional computed tomography mapping of posterior malleolar fractures.

Journal: World journal of clinical cases

Published: October 09, 2019

MicroRNA-28-5p Regulates Liver Cancer Stem Cell Expansion via IGF-1 Pathway.

MicroRNA-28-5p Regulates Liver Cancer Stem Cell Expansion via IGF-1 Pathway.

Journal: Stem cells international

Published: June 21, 2019

Showing 1-12 of 37

Last Updated: 09/26/2026